Kassberg Thomas Richard's Form 4 filing
Ultragenyx Pharmaceutical Inc. (RARE) · filed Mar 4, 2025
- Accession no.
- 0000950170-25-032802
- Filed
- Mar 4, 2025
- Trade date
- Mar 1-3, 2025
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions and 0 derivative transactions. Open-market sales total $253.8K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kassberg Thomas RichardCIK 0001303811 | Officer (CBO & EVP) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 1, 2025 | Common Stock | AGrant or awardAcquired | +18,443 | $0.00 | $0 | 271,266 | Direct | |
| Mar 3, 2025 | Common Stock | SSaleDisposed | −6,028 | $42.10 | −$253,778.8 | 265,238 | Direct | |
| Mar 3, 2025 | Common Stock | FTax withholdingDisposed | −508 | $42.92 | −$21,803.36 | 264,730 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.